Metformin reduces all-cause mortality and diseases of ageing independent of its effect on diabetes control: A systematic review and meta-analysis - PubMed

Review

Metformin reduces all-cause mortality and diseases of ageing independent of its effect on diabetes control: A systematic review and meta-analysis

Jared M Campbell et al. Ageing Res Rev. 2017 Nov.

Abstract

This systematic review investigated whether the insulin sensitiser metformin has a geroprotective effect in humans. Pubmed and Embase were searched along with databases of unpublished studies. Eligible research investigated the effect of metformin on all-cause mortality or diseases of ageing relative to non-diabetic populations or diabetics receiving other therapies with adjustment for disease control achieved. Overall, 260 full-texts were reviewed and 53 met the inclusion criteria. Diabetics taking metformin had significantly lower all-cause mortality than non-diabetics (hazard ratio (HR)=0.93, 95%CI 0.88-0.99), as did diabetics taking metformin compared to diabetics receiving non-metformin therapies (HR=0.72, 95%CI 0.65-0.80), insulin (HR=0.68, 95%CI 0.63-0.75) or sulphonylurea (HR=0.80, 95%CI 0.66-0.97). Metformin users also had reduced cancer compared to non-diabetics (rate ratio=0.94, 95%CI 0.92-0.97) and cardiovascular disease (CVD) compared to diabetics receiving non-metformin therapies (HR=0.76, 95%CI 0.66-0.87) or insulin (HR=0.78, 95%CI 0.73-0.83). Differences in baseline characteristics were observed which had the potential to bias findings, although statistical adjustments were made. The apparent reductions in all-cause mortality and diseases of ageing associated with metformin use suggest that metformin could be extending life and healthspans by acting as a geroprotective agent.

Keywords: Geroprotection; Insulin sensitizer; Lifespan; Longevity; Metformin; ageing.

Similar articles

• Mortality outcomes of different sulphonylurea drugs: the results of a 14-year cohort study of type 2 diabetic patients.

  Bo S, Castiglione A, Ghigo E, Gentile L, Durazzo M, Cavallo-Perin P, Ciccone G. Bo S, et al. Eur J Endocrinol. 2013 Jun 7;169(1):117-26. doi: 10.1530/EJE-13-0299. Print 2013 Jul. Eur J Endocrinol. 2013. PMID: 23660643

• All-cause and cardiovascular mortality associated with sulphonylurea and metformin therapy in type 2 diabetes.

  Ioacara S, Guja C, Reghina A, Martin S, Sirbu A, Fica S. Ioacara S, et al. Endocr Res. 2018 May;43(2):97-105. doi: 10.1080/07435800.2017.1422745. Epub 2018 Jan 8. Endocr Res. 2018. PMID: 29308936

• Systematic review and meta-analysis of the effect of metformin treatment on overall mortality rates in women with endometrial cancer and type 2 diabetes mellitus.

  Perez-Lopez FR, Pasupuleti V, Gianuzzi X, Palma-Ardiles G, Hernandez-Fernandez W, Hernandez AV. Perez-Lopez FR, et al. Maturitas. 2017 Jul;101:6-11. doi: 10.1016/j.maturitas.2017.04.001. Epub 2017 Apr 8. Maturitas. 2017. PMID: 28539171 Review.

• Long-term metformin use reduces gastric cancer risk in type 2 diabetics without insulin treatment: a nationwide cohort study.

  Kim YI, Kim SY, Cho SJ, Park JH, Choi IJ, Lee YJ, Lee EK, Kook MC, Kim CG, Ryu KW, Kim YW. Kim YI, et al. Aliment Pharmacol Ther. 2014 Apr;39(8):854-63. doi: 10.1111/apt.12660. Epub 2014 Feb 20. Aliment Pharmacol Ther. 2014. PMID: 24612291

• [Molecular action of insulin-sensitizing agents].

  Kacalska O, Krzyczkowska-Sendrakowska M, Milewicz T, Zabińska-Popiela M, Bereza T, Krzysiek-Maczka G, Krzysiek J. Kacalska O, et al. Endokrynol Pol. 2005 May-Jun;56(3):308-13. Endokrynol Pol. 2005. PMID: 16350724 Review. Polish.

Cited by

• Exercise-Pharmacology Interactions: Metformin, Statins, and Healthspan.

  Miller BF, Thyfault JP. Miller BF, et al. Physiology (Bethesda). 2020 Sep 1;35(5):338-347. doi: 10.1152/physiol.00013.2020. Physiology (Bethesda). 2020. PMID: 32783612 Free PMC article. Review.

• Genetics and epigenetics of diabetes and its complications in India.

  Priyadarshini A, Madan R, Das S. Priyadarshini A, et al. Hum Genet. 2024 Jan;143(1):1-17. doi: 10.1007/s00439-023-02616-3. Epub 2023 Nov 24. Hum Genet. 2024. PMID: 37999799 Review.

• Effect of metformin on all-cause and cardiovascular mortality in patients with coronary artery diseases: a systematic review and an updated meta-analysis.

  Han Y, Xie H, Liu Y, Gao P, Yang X, Shen Z. Han Y, et al. Cardiovasc Diabetol. 2019 Jul 30;18(1):96. doi: 10.1186/s12933-019-0900-7. Cardiovasc Diabetol. 2019. PMID: 31362743 Free PMC article.

• Unraveling female reproductive senescence to enhance healthy longevity.

  Dong L, Teh DBL, Kennedy BK, Huang Z. Dong L, et al. Cell Res. 2023 Jan;33(1):11-29. doi: 10.1038/s41422-022-00718-7. Epub 2023 Jan 2. Cell Res. 2023. PMID: 36588114 Free PMC article. Review.

• Review of Interventions for the Frailty Syndrome and the Role of Metformin as a Potential Pharmacologic Agent for Frailty Prevention.

  Espinoza SE, Jiwani R, Wang J, Wang CP. Espinoza SE, et al. Clin Ther. 2019 Mar;41(3):376-386. doi: 10.1016/j.clinthera.2019.01.006. Epub 2019 Mar 7. Clin Ther. 2019. PMID: 30851950 Free PMC article. Review.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • ClinicalKey
  • Elsevier Science

• Other Literature Sources

  • scite Smart Citations

• Medical

  • MedlinePlus Health Information

• Miscellaneous

  • NCI CPTAC Assay Portal